Cancer Drug Proves to Be Effective Against Multiple Tumors
The drug, pembrolizumab, sold as Keytruda, is the first approved for patients with tumors with a particular genetic signature, wherever they appear in the body. Just 4 percent of cancer patients have the type of genetic aberration susceptible to pembrolizumab. But that adds up to a lot of patients: as many as 60,000 each year in the United States alone, the study’s investigators estimated.
No comments:
Post a Comment